Synhealer

Synhealer LTD is at the forefront of next-generation immuno-oncology, pioneering CAR-macrophage (CAR-M) therapies specifically designed to target solid tumors. Our primary  focus is on liver cancer (HCC) patients who are resistant to current treatment such as immune checkpoint inhibitors.

Why Synhealer

•The world’s first EPSC-derived CAR-M therapy

•First CAR-M Company headquartered in HK

•Dual targeting approach via engineered antibody-secreting CAR-M combining antibody technology (AB) with CAR-M

Our innovative CAR-M therapy enhances tumor targeting and immune activation, tackling solid tumours that evade conventional treatments.